| 1.35 -0.01 (-0.74%) | 03-02 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 2.11  |
1-year : | 2.73 |
| Resists | First : | 1.8 |
Second : | 2.33 |
| Pivot price | 1.34 |
|||
| Supports | First : | 0.95 | Second : | 0.79 |
| MAs | MA(5) : | 1.35 |
MA(20) : | 1.42 |
| MA(100) : | 1.93 |
MA(250) : | 0 | |
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 51.6 |
D(3) : | 49.3 |
| RSI | RSI(14): 45.5 |
|||
| 52-week | High : | 4.03 | Low : | 0.95 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ APUS ] has closed below upper band by 46.0%. Bollinger Bands are 38.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.45 - 1.46 | 1.46 - 1.46 |
| Low: | 1.26 - 1.27 | 1.27 - 1.27 |
| Close: | 1.36 - 1.37 | 1.37 - 1.38 |
Apimeds Pharmaceuticals US, Inc. operates as a clinical stage biopharmaceutical company in the United States. It researches, develops, manufactures, commercializes, and sells Apitox, an active pharmaceutical ingredient for the treatment of inflammation and pain management symptoms associated with osteoarthritis and multiple sclerosis. The company was incorporated in 2020 and is based in Hopewell, New Jersey. Apimeds Pharmaceuticals US, Inc. is a subsidiary of Api Meds, Inc.
Tue, 24 Feb 2026
APUS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Thu, 19 Feb 2026
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Wed, 11 Feb 2026
Apimeds Pharmaceuticals reshapes board after director removal - MSN
Wed, 11 Feb 2026
Non-opioid arthritis therapy from bee venom heads to FDA meeting - Stock Titan
Wed, 10 Dec 2025
Apimeds Pharmaceuticals closes $100 million PIPE financing - Investing.com
Mon, 01 Dec 2025
Apimeds and MindWave to Merge - citybiz
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
AMEX
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|